Good evening :)
$
₹
Natera Inc

Natera Inc

NTRA

NASDAQ
Asset Logo

Natera Inc

NTRA

NASDAQ
$359.708.01% (-31.32)
$
₹
$359.708.01% (-31.32)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $56.0B the stock is ranked 304

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

29.98
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.35
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-7.11%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 23 analysts reports

Buy
21 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+6.48%

Earnings Growth

+4.39%

Rev. Growth

+26.2%

See Detailed Forecast

Company Profile

Company Profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 6.48% growth, versus a trailing 3-year CAGR of 108.57%.

2026
Current$391.03Baseline
Analyst Target - 1 year
Target$416.39+6.48%

All values in $

202220232024202520262027$141.62$247.09$352.56Target+6.48%
2026
Current$391.03Baseline
Analyst Target - 1 year
Target$416.39+6.48%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 26.20% growth, versus a trailing 3-year CAGR of 41.14%.

2025
Current$2.30Baseline
Forecast for Dec 2026
High$2.97+28.82%
Average$2.91+26.2%
Low$2.88+25.2%

All values in $ Billion

2021202220232024202520260.620.821.081.692.30Low+25.2%Average+26.2%High+28.82%
2025
Current$2.30Baseline
Forecast for Dec 2026
High$2.97+28.82%
Average$2.91+26.2%
Low$2.88+25.2%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.53Baseline
Forecast for Dec 2026
High$-0.63+58.82%
Average$-1.46+4.39%
Low$-2.02-32.03%

All values in $

202120222023202420252026-5.17-5.57-3.79-1.53-1.53Low-32.03%Average+4.39%High+58.82%
2025
Current$-1.53Baseline
Forecast for Dec 2026
High$-0.63+58.82%
Average$-1.46+4.39%
Low$-2.02-32.03%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

592.1
-87.5
665.5
47.2
696.6
-85
752.7
-66.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue367.74413.35439.75476.06501.83546.6592.18665.5696.64752.75
Net Income-67.59-37.46-31.59-53.77-66.93-100.93-87.5447.25-85.09-66.96
Net Profit Margin-18.38%-9.06%-7.18%-11.29%-13.33%-18.46%-14.78%7.10%-12.21%-8.89%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Natera Inc -29.980
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare NTRA with any stock or ETF
Compare NTRA with any stock or ETF
Comparing from
NTRA
ABBV
AMGN
Loading...

Frequently asked questions

  1. Natera Inc (NTRA) share price today is $359.70 as of November 5, 2026 at 9:27 PM IST. The stock touched a day high of $372.56 and a day low of $357.14.

  2. Natera Inc stock trades on NASDAQ under the ticker symbol NTRA.

  3. Natera Inc's market capitalization is $56.01B as of November 5, 2026 at 9:27 PM IST.

  4. Natera Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Natera Inc's price-to-book (P/B) ratio is 29.98 as of November 5, 2026.

  6. Yes, You can buy Natera Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Natera Inc shares in three steps: 1. Search Natera Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Natera Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Natera Inc (NTRA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0278 shares at the current price of $359.70.

Loading...